Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stellar Announces Chow and Brisson to New C-Level Posts

Published: Tuesday, August 14, 2012
Last Updated: Tuesday, August 14, 2012
Bookmark and Share
Herbert S. Chow and Catherine Brisson appointed to the position of CTO and CPO respectively.

Stellar Biotechnologies, Inc. has announced that Herbert S. Chow, Ph.D. has been appointed to the position of Chief Technology Officer (CTO) and Catherine Brisson, Ph.D. has been appointed the position of Chief Pharmaceutical Officer (CPO) for the Company.

Stellar’s President & CEO, Frank Oakes said, “This is an important move for Stellar as it fills two key positions on senior management team with two extremely talented professionals with extensive experience in the science and technology surrounding KLH, and a deep understanding of our strategic pathway and product pipeline. I do not believe the Company could have found two more qualified candidates to meet the challenges of these two key positions and support the effective execution of the company’s plan over the next few years.”

New CPO, Catherine Brisson said, “I am very excited to be a part of this technology which perfectly fits the needs of the pharmaceutical industry. I feel confident that my commercial development expertise and strategic insight will contribute to Stellar’s immediate and future successes. I am pleased to be working in this new capacity with the first-class team of scientific, engineering, and business leaders that Stellar has assembled-all focused on tackling a challenging but critically important mission of advancing the innovative KLH therapeutic platform.”

New CTO, Herbert Chow said, “I am looking forward to working with the management team, our Board and Scientific Advisory Board to design and advance an innovative pipeline of KLH based vaccine candidates for the diagnosis and treatment of serious indications with a huge unmet medical need. I am excited to face the challenges ahead and to lead the development of the next generation of infectious disease and oncology vaccine solutions.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stellar and Neovacs Propose to Form Joint Venture
Joint venture to manufacture conjugated therapeutic vaccines with Stellar KLH™.
Saturday, January 23, 2016
Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology
Issuance of two additional patents in U.S. and China.
Tuesday, December 10, 2013
Stellar Presents Preclinical Poster on C. diff Active Immunotherapy
Poster presented at 7th Vaccine and ISV Congress being held in Spain.
Tuesday, October 29, 2013
Stellar’s Immunotherapy Technology Demonstrates Protection Against C. diff Infection
Study results presented this week at ClostPath 8 in Australia, October 22-26, 2013.
Tuesday, October 22, 2013
Stellar Acquires Exclusive, Worldwide License to C. diff Immunotherapy Technology
Stellar expands with proprietary KLH-based vaccine program.
Wednesday, July 31, 2013
Stellar Announces New Board Members
Appointment of Gregory T. Baxter and Mike Sampat to Board.
Wednesday, August 22, 2012
Stellar Announces Exclusive Option to License Clostridium Difficile Technology
Stellar executes agreement with University of Guelph for vaccine research.
Wednesday, April 11, 2012
Stellar Biotechnologies Announces Investor Relations Agreement
Stellar Biotechnologies, Inc. is pleased to announce that it has retained TheBiotechPanel, Inc. to provide the Company with investor relations services, for an initial period of six months.
Wednesday, January 18, 2012
Stellar Biotechnologies Announces a Strategic Agreement for Marketing and Sales with SAFC®
Stellar will produce KLH commercial intermediate and SAFC will sell, distribute and market cGMP-grade HMW KLH.
Friday, August 05, 2011
Stellar Biotechnologies Announces Appointment of New Director, David L. Hill, Ph. D.
Dr. Hill, is a Board Certified High Complexity Laboratory Director, Board Certified Embryology Laboratory Director and member of the American Association of Bioanalysts.
Friday, May 27, 2011
Stellar Biotechnologies Appoints Vice President, Business Development & Marketing
Company Executive VP, Darrell Brookstein's title will be changed to Executive VP, Corporate Development & Finance.
Wednesday, March 09, 2011
Scientific News
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Immunotherapy Reduces Rheumatoid-Linked Cardiovascular Risk
Study shows combination of two extra-low dose anticytokines reduces disease activity and cardiovascular events.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
Sanofi Working on Zika Vaccine with U.S. Army
Sanofi is working in conjunction with the U.S. Army to develop possible Zika vaccine at faster rate following research agreement.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!